Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2003 2
2004 1
2005 1
2006 2
2008 2
2009 1
2010 1
2011 2
2012 6
2013 4
2014 3
2015 4
2016 3
2017 5
2018 4
2019 3
2021 4
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Memantine for dementia.
McShane R, Westby MJ, Roberts E, Minakaran N, Schneider L, Farrimond LE, Maayan N, Ware J, Debarros J. McShane R, et al. Cochrane Database Syst Rev. 2019 Mar 20;3(3):CD003154. doi: 10.1002/14651858.CD003154.pub6. Cochrane Database Syst Rev. 2019. PMID: 30891742 Free PMC article.
Mild AD (Mini Mental State Examination (MMSE) 20 to 23): mainly moderate-certainty evidence based on post-hoc subgroups from up to four studies in around 600 participants suggests there is probably no difference between memantine and placebo for CF: 0.21 ADAS-Cog points (9 …
Mild AD (Mini Mental State Examination (MMSE) 20 to 23): mainly moderate-certainty evidence based on post-hoc subgroups from up to four stud …
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
The primary outcome measures were scores on the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog11, with scores ranging from 0 to 70 and higher scores indicating greater impairment) and the Disability Assessment for Dementia (DAD, with score …
The primary outcome measures were scores on the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog11, w …
The impact of individual Cognitive Stimulation Therapy (iCST) on cognition, quality of life, caregiver health, and family relationships in dementia: A randomised controlled trial.
Orrell M, Yates L, Leung P, Kang S, Hoare Z, Whitaker C, Burns A, Knapp M, Leroi I, Moniz-Cook E, Pearson S, Simpson S, Spector A, Roberts S, Russell I, de Waal H, Woods RT, Orgeta V. Orrell M, et al. PLoS Med. 2017 Mar 28;14(3):e1002269. doi: 10.1371/journal.pmed.1002269. eCollection 2017 Mar. PLoS Med. 2017. PMID: 28350796 Free PMC article. Clinical Trial.
Primary outcomes were cognition (Alzheimer's Disease Assessment Scale-cognitive [ADAS-Cog]) and self-reported QoL (Quality of Life Alzheimer's Disease [QoL-AD]) for the person with dementia and general health status (Short Form-12 health survey [SF-12]) for the caregiver. …
Primary outcomes were cognition (Alzheimer's Disease Assessment Scale-cognitive [ADAS-Cog]) and self-reported QoL (Quality of Life Al …
Administration and scoring variance on the ADAS-Cog.
Connor DJ, Sabbagh MN. Connor DJ, et al. J Alzheimers Dis. 2008 Nov;15(3):461-4. doi: 10.3233/jad-2008-15312. J Alzheimers Dis. 2008. PMID: 18997299 Free PMC article.
The Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog) is the most commonly used primary outcome instrument in clinical trials for treatments of dementia. Variations in forms, administration procedures and scoring rules, along with rater turnover and intra-rater d …
The Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog) is the most commonly used primary outcome instrument in clinical tria …
The Alzheimer's Disease Assessment Scale-Cognitive-Plus (ADAS-Cog-Plus): an expansion of the ADAS-Cog to improve responsiveness in MCI.
Skinner J, Carvalho JO, Potter GG, Thames A, Zelinski E, Crane PK, Gibbons LE; Alzheimer's Disease Neuroimaging Initiative. Skinner J, et al. Brain Imaging Behav. 2012 Dec;6(4):489-501. doi: 10.1007/s11682-012-9166-3. Brain Imaging Behav. 2012. PMID: 22614326 Free PMC article.
RESULTS: The selected EF candidate added category fluency (ADAS Plus EF), and the selected EF and FA candidate added category fluency, Digit Symbol, Trail Making, and five items from the Functional Assessment Questionnaire (ADAS Plus EF&FA). The ADAS Plus …
RESULTS: The selected EF candidate added category fluency (ADAS Plus EF), and the selected EF and FA candidate added category fluency …
Statin therapy in Alzheimer's disease.
Sparks DL, Sabbagh M, Connor D, Soares H, Lopez J, Stankovic G, Johnson-Traver S, Ziolkowski C, Browne P. Sparks DL, et al. Acta Neurol Scand Suppl. 2006;185:78-86. doi: 10.1111/j.1600-0404.2006.00689.x. Acta Neurol Scand Suppl. 2006. PMID: 16866915 Review.
We demonstrated that atorvastatin treatment produced significantly (P = 0.003) improved performance on cognition and memory after 6 months of treatment (ADAS-cog) among patients with mild-to-moderate AD. This superior effect persisted at 1 year (P = 0.055). This positive e …
We demonstrated that atorvastatin treatment produced significantly (P = 0.003) improved performance on cognition and memory after 6 months o …
Challenges in developing antidrug antibody screening assays.
Dodge R, Daus C, Yaskanin D. Dodge R, et al. Bioanalysis. 2009 Jul;1(4):699-704. doi: 10.4155/bio.09.55. Bioanalysis. 2009. PMID: 21083131 Review.
Robert Dodge is the Laboratory Director for Immunochemistry and Cell Biology at Taylor Technology, a Pharmanet company in Princeton, NJ, USA. ...Protein drugs may elicit an immune response in the form of production of antidrug antibodies (ADAs) by a subject. This AD …
Robert Dodge is the Laboratory Director for Immunochemistry and Cell Biology at Taylor Technology, a Pharmanet company in Princeton, …
Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease.
Ihl R, Ferris S, Robert P, Winblad B, Gauthier S, Tennigkeit F. Ihl R, et al. Int J Geriatr Psychiatry. 2012 Jan;27(1):15-21. doi: 10.1002/gps.2679. Epub 2011 Mar 8. Int J Geriatr Psychiatry. 2012. PMID: 21384431
OBJECTIVE: When complex cognitive functions are measured with multi-item scales like the Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog), it seems valuable information can be lost due to combination of the ADAS-cog items results into a total sco …
OBJECTIVE: When complex cognitive functions are measured with multi-item scales like the Alzheimer's Disease Assessment Scale - cognitive su …
Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction.
Kishnani PS, Dickson PI, Muldowney L, Lee JJ, Rosenberg A, Abichandani R, Bluestone JA, Burton BK, Dewey M, Freitas A, Gavin D, Griebel D, Hogan M, Holland S, Tanpaiboon P, Turka LA, Utz JJ, Wang YM, Whitley CB, Kazi ZB, Pariser AR. Kishnani PS, et al. Mol Genet Metab. 2016 Feb;117(2):66-83. doi: 10.1016/j.ymgme.2015.11.001. Epub 2015 Nov 10. Mol Genet Metab. 2016. PMID: 26597321 Review.
The US Food and Drug Administration (FDA) and National Organization for Rare Disease (NORD) convened a public workshop titled "Immune Responses to Enzyme Replacement Therapies: Role of Immune Tolerance Induction" to discuss the impact of anti-drug antibodies (ADAs) on effi …
The US Food and Drug Administration (FDA) and National Organization for Rare Disease (NORD) convened a public workshop titled "Immune Respon …
Advanced driver assistance systems for teen drivers: Teen and parent impressions, perceived need, and intervention preferences.
Weiss E, Fisher Thiel M, Sultana N, Hannan C, Seacrist T. Weiss E, et al. Traffic Inj Prev. 2018 Feb 28;19(sup1):S120-S124. doi: 10.1080/15389588.2017.1401220. Traffic Inj Prev. 2018. PMID: 29584476
Yet, ADAS is only effective if drivers are willing to use it. Limited research has been conducted on the suitability of ADAS for teen drivers. ...They expressed that novice drivers should learn to drive on non-ADAS-equipped cars and that ADAS should be …
Yet, ADAS is only effective if drivers are willing to use it. Limited research has been conducted on the suitability of ADAS f …
46 results